SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/05/20 Teladoc Health, Inc. 8-K:7,9 3/05/20 11:30M Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 29K 2: EX-99.1 Miscellaneous Exhibit HTML 82K 11: R1 Cover HTML 49K 9: XML IDEA XML File -- Filing Summary XML 11K 7: XML XBRL Instance -- tm2011736-1_8k_htm XML 15K 8: EXCEL IDEA Workbook of Financial Reports XLSX 6K 4: EX-101.LAB XBRL Labels -- tdoc-20200305_lab XML 96K 5: EX-101.PRE XBRL Presentations -- tdoc-20200305_pre XML 64K 3: EX-101.SCH XBRL Schema -- tdoc-20200305 XSD 12K 10: JSON XBRL Instance as JSON Data -- MetaLinks 25± 33K 6: ZIP XBRL Zipped Folder -- 0001104659-20-029467-xbrl Zip 23K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) i March 5, 2020
(Exact name of registrant as specified in its charter)
i Delaware | i 001-37477 | i 04-3705970 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
i 2 Manhattanville Road, i Suite 203 i Purchase, i New York |
i 10577 | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
i Common Stock, par value $0.001 per share | i TDOC | i The New York Stock Exchange |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01. Regulation FD.
As previously announced, on March 5, 2020, Teladoc Health, Inc. (the “Company”) will host an investor day (the “Investor Day”) in New York City, New York, beginning at 10:00 a.m. Eastern Time. A copy of the materials to be presented by the Company at the Investor Day is furnished herewith as Exhibit 99.1. There will be a live audio webcast of the Investor Day accessible via the Company’s Investor Relations website at http://ir.teladoc.com. The Company reserves the right to discontinue the availability of the materials and webcast at any time.
The information furnished under this Item 7.01 of this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
Description | |
99.1 | Teladoc Health, Inc. slide presentation, dated March 5, 2020. | |
104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TELADOC HEALTH, INC. | ||
Date: March 5, 2020 | By: | /s/ Adam C. Vandervoort |
Name: | Adam C. Vandervoort | |
Title: | Chief Legal Officer and Secretary |
C:
C:
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on / For Period end: | 3/5/20 | 4 | ||
List all Filings |